In Brief: Gingrich ethics probe
This article was originally published in The Gray Sheet
Executive SummaryGingrich ethics probe: House Committee on Standards of Official Conduct, which is investigating charges of ethics violations involving House Speaker Newt Gingrich (R-Ga.), dismisses "the allegation of improper intervention with the Executive branch for a donor to the Progress and Freedom Foundation (Direct Access Diagnostics)," the committee said in a Dec. 6 letter to the speaker. Elliott Millenson, former CEO and president of the Johnson & Johnson subsidiary, testified before the committee Nov. 29. He reportedly discussed contributions that he, Direct Access and J&J made to the Progress and Freedom Foundation -- a conservative think tank with close ties to the speaker -- and a possible link between the contributions and Gingrich's query to the White House on the status of DAD's Confide home-use HIV specimen collection kit...
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.